The tweet was deleted by the author.
But we saved everything 🙂.
Agenus announced that Armenia has granted its first marketing authorizations for BOT plus BAL in adults with previously treated microsatellite stable metastatic colorectal cancer (MSS mCRC) without active liver metastases.
The regulatory milestone marks a notable expansion for Agenus's oncology portfolio and access in the region. Further details regarding the commercial rollout or patient access have not been disclosed.
View post on X Loading...
Agenus previously shared an update on the execution of its ROBBIN Phase 3 trial and the BOT+BAL immunotherapy strategy in colorectal cancer, according to company disclosures. In separate developments, the firm reported 48 percent three-year overall survival in a Phase 1b ovarian cancer study, matching year-two results, as detailed in recent follow-up data. These milestones continue to inform Agenus’s expansion in oncology indications.